Abstract:Abstract Background Short-chain fatty acids (SCFAs), the main metabolites produced by bacterial fermentation of dietary fiber, possess neuroactive properties. The present study aimed to explore whether SCFAs-butyrate can repress neuroinflammation and alleviate cognitive impairment via improving gut mucosal barrier function and mediating tryptophan metabolism in LDLR−/− mice. Methods LDLR−/− mice were fed an atherosclerotic diet with 1.25% cholesterol and 40% calories from fat and concomitantly treated by intragastric administration with either normal saline as model group or 400mg/kg/day sodium butyrate for 8 weeks. Results For gut barrier function, butyrate increased expression of tight junction protein, and inhibited intestinal inflammatory pathways by targeting the toll-like receptor 4 signaling and the nod-like receptors domain containing 3 (NLRP3) inflammasome. Subsequently, butyrate reduced not only the serum lipopolysaccharide level but also its capability to cross the blood-brain barrier, leading to the suppression of tau phosphorylation and the improvement of neuroinflammation by inhibiting the increase in reactive microglia and astrocytes, and blocking NLRP3 inflammasome activation in the cortex and hippocampus. Final behavioral tests indicated that butyrate delayed cognitive impairment via decreasing latency to the platform and lengthening swimming distance in the target quadrant. Nevertheless, butyrate showed no effect on serotonin, indoleacetic acid, L-kynurenine, niacinamide, and their metabolites, indicating that the observed effects on cognitive function are unrelated to the tryptophan metabolism. Conclusion In summary, the present study provided the novel experimental evidence that butyrate played a neuroprotective role by targeting the NLRP3 inflammasome. The reduction of neuroinflammation may be related to the improvement of gut mucosal barrier function and the decrease of the penetration of intestinal endotoxin from the gut to the central nervous system.

A new paradigm for a new simple chemical: butyrate & immune regulation

Regulation of immune cell function by short-chain fatty acids

Protective role of butyrate in obesity and diabetes: New insights

Butyrate Prevents the Pathogenic Anemia‐Inflammation Circuit by Facilitating Macrophage Iron Export

Butyrate Properties in Immune-Related Diseases: Friend or Foe?

Regulation of short-chain fatty acids in the immune system

The interplay between gut microbiota, short-chain fatty acids, and implications for host health and disease

SCFA: mechanisms and functional importance in the gut

Short-chain fatty acid-mediated epigenetic modulation of inflammatory T cells in vitro

Short-chain fatty acids: linking diet, the microbiome and immunity

P036 Microbiota Metabolite Butyrate Attenuates Intestinal Inflammation Through Autophagy Activation

A major mechanism for immunomodulation: Dietary fibres and acid metabolites

Butyrate Alleviates Cognitive Impairment by Improving Gut Mucosal Barrier Function and Blocking Neuroinflammatory Signaling in LDLR-/- Mice

Butyrate Inhibits the HDAC8/NF-κB Pathway to Enhance Slc26a3 Expression and Improve the Intestinal Epithelial Barrier to Relieve Colitis

Butyrate and Propionate Protect against Diet-Induced Obesity and Regulate Gut Hormones via Free Fatty Acid Receptor 3-Independent Mechanisms

Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease

The emerging role of microbiota-derived short-chain fatty acids in immunometabolism

Butyrate and obesity: Current research status and future prospect

The Role of Short Chain Fatty Acids in Inflammation and Body Health

Modulation of lipid synthesis, apolipoprotein biogenesis, and lipoprotein assembly by butyrate

Short chain fatty acids regulation of neutrophil production of IL-10